Efficacy and Safety of Ripretinib vs. Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumor Previously Treated with Imatinib: A Phase 2, Multicenter, Randomized, Open-Label Study in China
Jian Li,Jun Zhang,Yanqiao Zhang,Haibo Qiu,Yanbing Zhou,Yongjian Zhou,Xinhua Zhang,Ye Zhou,Yuping Zhu,Yong Li,Ming Wang,Kuntang Shen,Kaixiong Tao,Xin Wu,Haijiang Wang,Bo Zhang,Jiayu Ling,Yingjiang Ye,Xingye Wu,Hongyan Qu,Yue Ma,Xuelong Jiao,Hualong Zheng,Jiejie Jin,Zhuo Liu,Ming Tan,Yong Fang,Peng Zhang,Nan Zhang,Cheng Lei,Zhaolun Cai,Bin Liang,Zhangyan Peng,Zhao Huang,Juan Dong,Lin Shen
DOI: https://doi.org/10.1016/j.ejca.2023.113439
IF: 10.002
2023-11-16
European Journal of Cancer
Abstract:Aim A bridging study of INTRIGUE study to assess the efficacy and safety of ripretinib versus sunitinib as second-line treatment in Chinese GIST patients. Methods This was a phase 2, multicenter, randomized, open-label study in China. GIST patients previously treated with imatinib were randomized (1:1) to receive ripretinib 150 mg once daily (QD) by continuous dosing in 42-day cycles or sunitinib 50 mg QD in 42-day cycles (four weeks on/two weeks off). Primary endpoint was progression-free survival (PFS) by independent radiological review (IRR). Results Between 6 December 2020 and 15 September 2021, 108 patients were randomized to receive ripretinib (n=54) or sunitinib (n=54) (all-patient [AP] intention-to-treat [ITT] population). Seventy patients had primary KIT exon 11 mutations (ripretinib, n = 35; sunitinib, n = 35; Ex11 ITT population). By data cut-off (20 July 2022), in AP ITT population, PFS by IRR was comparable between ripretinib and sunitinib arms (HR 0·99, 95% CI 0·57, 1·69; nominal p = 0·92; median PFS [mPFS] 10·3 vs 8·3 months). In Ex11 ITT population, PFS by IRR was longer for ripretinib than sunitinib (HR 0·46, 95% CI 0·23, 0·92; nominal p = 0·03; mPFS not reached in ripretinib arm and 4·9 months in sunitinib arm). Fewer patients experienced grade 3/4 treatment-related treatment-emergent adverse events with ripretinib (17%) versus sunitinib (56%). Conclusions Ripretinib demonstrated similar efficacy and a favorable safety profile versus sunitinib as second-line treatment in Chinese GIST patients. Furthermore, ripretinib provided greater clinically meaningful benefit versus sunitinib in patients with KIT exon 11 mutation.
oncology